Lung Cancer Clinical Trials & Research at Providence Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
Providence Medical Group is currently enrolling patients for the following
lung cancer clinical trials:
A study for patients with unresectable Stage IIIB non small cell lung cancer
after chemotherapy and radiation: AZ D9075C00001- PACIFIC 8
Treatment agent: Durvalumab
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following
Concurrent Chemoradiation in Participants With Stage III Unresectable
NSCLC - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy
With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer
Patients Who Are PD-L1 Negative (Alliance A082002)
Treatment agent: Radiotherapy + Immunotherapy (+/- Chemotherapy)
Physician:
Michael N. Corradetti
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
https://clinicaltrials.gov/study/NCT04929041
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials
in Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA
Study for participants with unresectable Pleural Mesothelioma (eVOLVE-Meso)
Treatment agent: Volrustomig (MEDI5752) in Combination with Carboplatin
plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab
Physician: Dr Ian Anderson
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | MEDI5752 in Combination With Carboplatin Plus Pemetrexed
in Unresectable Pleural Mesothelioma | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the
Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects
with Solid Tumors or Lymphoma
Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician:
Ian Anderson, MD
Study Coordinator: Melissa Ulrich //
melissa.ulrich@providence.org // 707-521-3830
Study Resources:
Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression
Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA
A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug
Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono
MS202329-0010 PROCEADE)
Treatment agent: Anti-CEACAM5 Antibody-Drug Conjugate M9140
Physician:
Ian Anderson, MD
Study Coordinator: Aubrey Adiao //
aubrey.adiao@providence.org // 707-521-3830
Study Resources:
Study Details | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced
Solid Tumors (PROCEADE PanTumor) | ClinicalTrials.gov
Sponsor: EMD Serono Research & Development Institute, Inc
Location: Providence Cancer Center, Santa Rosa, CA
Bluestar study to test a new drug in participants with advanced or metastatic
ovarian, endometrial or HER2-breast cancer
Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC)
Physician:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
camille.shaffer@stjoe.org // 707-521-3830
Study Resources:
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic
Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort,
Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab
in Subjects with Locally Advanced or Metastatic Solid Tumors
Treatment agent: INBRX-106 (Hexavalent OX40 Agonist)
Physician:
Ian Anderson, MD
Study Coordinator: Aubrey Adiao //
aubrey.adiao@providence.org // 707-521-3830
Study Resources:
Study Details | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab
(Keytruda®) in Subjects With Locally Advanced or Metastatic Solid
Tumors (Hexavalent OX40 Agonist) | ClinicalTrials.gov
Sponsor: Inhibrx Biosciences, Inc
Location: Providence Cancer Center, Santa Rosa, CA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in
Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab
in Combination with Platinum- Based Chemotherapy as Second-line Treatment,
for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell
Lung Cancer (COPERNICUS)
Treatment agent: JNJ-61186372 (amivantamab) and JNJ-73841937 (lazertinib)
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Study of Amivantamab in Combination With Lazertinib,
or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common
Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic
Non-Small Cell Lung Cancer (NSCLC) | ClinicalTrials.gov
Sponsor: Janssen Research & Development, LLC
Location: Providence Cancer Center, Santa Rosa, CA
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab
Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy
for the First-line Treatment of Metastatic Non-small Cell Lung Cancer
Treatment agent: Ivonescimab
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | Clinical Study of Ivonescimab for First-line Treatment
of Metastatic NSCLC Patients | ClinicalTrials.gov
Sponsor: Summit Therapeutics
Location: Providence Cancer Center, Santa Rosa, CA
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy
in First-line HER2 Overexpressing Non-small Cell Lung Cancer (DESTINY-Lung06)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy
for First-Line Treatment of Metastatic Non-squamous NSCLC
Treatment agent: Rilvegostomig (AZD2936) - D702FC00001
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
Study Details | A Global Phase III Study of Rilvegostomig or Pembrolizumab
Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous
NSCLC | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations
in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
Treatment agent: AB248
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830Study Resources:
Sponsor:
Location: Providence Cancer Center, Santa Rosa, CA
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With
or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for
Participants with EGFR-mutated Locally Advanced or Metastatic Non-small
Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment
(TROPION-Lung15)